S&P 500
(0.13%) 5 187.70 points
Dow Jones
(0.08%) 38 884 points
Nasdaq
(-0.10%) 16 333 points
Oil
(-0.06%) $78.33
Gas
(0.54%) $2.22
Gold
(-0.03%) $2 323.50
Silver
(-0.21%) $27.49
Platinum
(0.01%) $988.50
USD/EUR
(0.06%) $0.930
USD/NOK
(0.22%) $10.92
USD/GBP
(0.09%) $0.800
USD/RUB
(0.01%) $91.45

Actualizaciones en tiempo real para Ocugen Inc [OCGN]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
BUY
100.00%
return 9.47%
SELL
100.00%
return -10.94%
Última actualización7 may 2024 @ 16:00

-3.68% $ 1.570

COMPRAR 119715 min ago

@ $0.657

Emitido: 14 feb 2024 @ 15:30


Retorno: 139.15%


Señal anterior: feb 14 - 09:30


Señal anterior: Vender


Retorno: 6.16 %

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 16:00):
Profile picture for Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...

Stats
Volumen de hoy 6.47M
Volumen promedio 10.13M
Capitalización de mercado 404.00M
EPS $-0.0300 ( 2024-05-03 )
Próxima fecha de ganancias ( $-0.0600 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.04
ATR14 $0.00700 (0.45%)
Insider Trading
Date Person Action Amount type
2024-04-16 Qamar Huma Buy 308 465 Option (Right to Buy)
2024-03-18 Qamar Huma Sell 0 Common Stock
2023-09-15 Breininger Michael Buy 0
2024-01-03 Musunuri Shankar Sell 180 204 Common Stock
2024-01-03 Upadhyay Arun Sell 41 633 Common Stock
INSIDER POWER
65.41
Last 96 transactions
Buy: 10 862 012 | Sell: 2 992 475

Volumen Correlación

Largo: 0.02 (neutral)
Corto: -0.61 (weak negative)
Signal:(47.399) Neutral

Ocugen Inc Correlación

10 Correlaciones Más Positivas
EQRR0.944
PVAL0.943
RNA0.942
THRN0.938
RAIL0.936
DVLU0.935
PCAR0.934
SG0.934
SHLD0.933
LFMDP0.932
10 Correlaciones Más Negativas
RMRM-0.938
RGC-0.934
UONEK-0.926
TCPC-0.922
VORB-0.921
TSP-0.919
BRQS-0.918
HCDIP-0.916
AGRX-0.91
QNRX-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ocugen Inc Correlación - Moneda/Commodity

The country flag 0.50
( neutral )
The country flag 0.78
( moderate )
The country flag 0.00
( neutral )
The country flag 0.73
( moderate )
The country flag 0.00
( neutral )
The country flag 0.05
( neutral )

Ocugen Inc Finanzas

Annual 2023
Ingresos: $6.04M
Beneficio Bruto: $5.33M (88.34 %)
EPS: $-0.260
FY 2023
Ingresos: $6.04M
Beneficio Bruto: $5.33M (88.34 %)
EPS: $-0.260
FY 2022
Ingresos: $0
Beneficio Bruto: $-1.07M (0.00 %)
EPS: $-0.360
FY 2021
Ingresos: $0.00
Beneficio Bruto: $0.00 (0.00 %)
EPS: $-0.300

Financial Reports:

No articles found.

Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico